Back
 

View:
Mini 
BasicThis view is available after user registration.
 
ShortThis view is available when you buy a license.
 
StandardThis view is available when you buy a license.
 
CompleteThis view is available when you buy a license.
 

Nivolumab 480, Renal Cell Carcinoma, Second Line

Protocol-ID: 1135 V1.0 (Mini), NIVO480, RCC, second line

Indication(s)

  • Renal Cell Carcinoma; ICD-10 C64

Links

  • Nivolumab (opdivo) [EMA EPAR]
  • Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing [URL]
The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 19.06.2018